PT-141
PT-141 (bremelanotide) is a melanocortin receptor agonist that acts on the central nervous system rather than blood flow — a mechanistic distinction from the standard ED drugs.
Also known as: Bremelanotide
Research context
- Acts on melanocortin receptors in the central nervous system.
- The basis of a US-approved prescription product.
- Single 10mg presentation.
PT-141
from £13.60 per vial
| Strength | Price | |
|---|---|---|
| 10mg | £13.60bank £12.24 | Buy vial |
Bank transfer prices shown under each card price (10% off). Checkout runs on Stripe; bank orders confirm on clearance.
Related compounds
What PT-141 is
PT-141 (bremelanotide) is a cyclic heptapeptide and a melanocortin receptor agonist. Its defining feature is where it acts: it works on the central nervous system through melanocortin receptors (chiefly MC4R), rather than on peripheral blood flow. That is the mechanistic line between PT-141 and the PDE5-inhibitor class, and it is why the two are treated as different research questions even when discussed together.
The compound's history is unusual. It began as a metabolite of melanotan II, a non-selective melanocortin agonist originally researched for pigmentation; the effect on sexual desire was an observed side-finding that became the compound's own research focus. Bremelanotide went on to become the basis of a US-approved prescription product, which is what separates it from most peptides on this site — but the approved product is a licensed medicine, and this listing is not.
The honest bound: despite that approved-product status, the published literature on bremelanotide itself is narrower than its profile suggests, weighted toward the clinical population studied in the approval programme rather than broad general use.
Where PT-141 sits in the catalogue
PT-141 is the melanocortin compound in our range. The distinguishing question is always which receptor system a compound acts on — not simply what it is marketed alongside:
| Compound | Class / mechanism | Volume of human evidence |
|---|---|---|
| PT-141 | Cyclic heptapeptide; melanocortin agonist (central) | Moderate — basis of a US-approved prescription product |
| Melanotan II | Non-selective melanocortin agonist | Early — research-use only, broader receptor activity |
| Kisspeptin-10 | Decapeptide; hypothalamic GnRH pathway | Early — a completely different signalling route |
Kisspeptin-10 sits upstream in the hypothalamic cascade; PT-141 acts directly on melanocortin receptors. They are sometimes discussed in the same breath, but they are not the same mechanism and should not be treated as substitutes.
Supply, handling and documentation
We supply PT-141 as a lyophilised (freeze-dried) powder in a sealed vial: a single 10mg presentation.
- Lyophilised powder: store sealed, refrigerated, protected from light.
- Reconstituted solution: refrigerate at 2–8°C and keep covered.
- Do not repeatedly warm and cool the vial; condensation degrades short peptides quickly.
Every batch ships with documentation available on request — see our lab and COA policy for what we will and will not claim, and the reconstitution guide for the method in detail.
Ordering, payment and delivery
Pricing is per vial, shown openly at the top of this page. Card checkout runs through Stripe. Bank transfer is offered at a 10% discount and prices are shown under each card price; bank orders are confirmed once funds clear. UK dispatch is same or next working day, with tracked delivery.
Delivery times and payment details are set out in full on the delivery page. If anything is unclear before ordering, contact us — we would rather answer a question than process a return.
PT-141: common questions
Is PT-141 the same as Melanotan II?
No. Melanotan II is a non-selective melanocortin agonist with broader receptor activity; PT-141 (bremelanotide) is a cyclic heptapeptide developed as a more selective melanocortin agonist. They are related but distinct compounds.
Is PT-141 a medicine?
The molecule is the basis of a US-approved prescription medicine, but what we supply is a research chemical. It is not a medicine, it is not for human or veterinary use, and nothing on this page is medical advice.
How does PT-141 differ from standard ED drugs?
Mechanistically. PT-141 acts centrally through melanocortin receptors, whereas PDE5 inhibitors act peripherally on blood flow. This is a difference in research mechanism, not a claim about effect.
Which sizes do you stock?
A single 10mg presentation, priced per vial above.
Does PT-141 need to be refrigerated?
Yes — sealed lyophilised vials should be refrigerated and kept out of light. Once reconstituted, keep at 2–8°C.
Do you provide a certificate of analysis?
Batch documentation is available on request. See the lab and COA policy for exactly what is provided and what is not.